17,261 trials
Renal Failure · End Stage Renal Disease · Vascular Access
Primary: Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAV — 0 participants
Advanced High-grade Ovarian Cancer · Triple Negative Breast Cancer
Primary: Phase 1: Number of Participants With Treatment- Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) — 4; 4; 7; 0 Number of participants
Leukemia, Myeloid, Acute
Primary: Primary Efficacy — 7 Participants
Immune Thrombocytopenia (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 0; 25 percentage of participants
Mammographically Dense Breast
Primary: Mammographic Breast Density Using Cumulus Software — -6.30; -5.77; -2.81; -5.43 Percent Change in Breast Density
Glabellar Frown Lines
Primary: Investigator's Rating of Glabellar Line Severity at Maximum Frown by Live Assessment. — 18; 18; 22; 19 Participants
Osteopenia · Osteoporosis
Primary: Lumbar Spine Bone Mineral Content — 41.4; 38.7 Average grams
Metastatic Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Immune RECIST (iRECIST) Criteria — 0 Participants
Refractory Large B-cell Lymphoma
Primary: Complete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators — 73 percentage of participants
Cancer · Prostate Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events — 10; 1; 2; 37 Participants
Crohn Disease
Primary: The Total Number of Deregulated Genes at Week 4 — 0; 0 Deregulated genes
Confirmed Coronavirus Disease
Primary: Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7 — 6; 0; 20; 8 Participants — p=0.0346
Fecal Incontinence
Primary: Number of Treatment-Related Adverse Events — 0; 1; 5; 28 events
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome
Primary: Failure-free Survival (Failure Defined as Death or Relapse) — 6; 10 Participants
Decrease in Night Vision · Disturbance; Vision, Loss
Primary: Contrast Sensitivity — 0.6; 0.8; 0.9; 0.7 Patches